Mylan Signs Strategic Alliance Agreement with Walt Disney Parks and Resorts to Enhance Access to EpiPen® (epinephrine) Auto-Injectors
PITTSBURGH, Nov. 7, 2014 /PRNewswire/ -- Mylan Inc. (MYL) today announced it has signed a multi-year strategic alliance agreement with Walt Disney Parks and Resorts to help increase awareness of anaphylaxis, a life-threatening (severe) allergic reaction. The agreement includes updated maps in Disney's domestic theme parks and on its cruise ships as well as updated signage in the parks that highlight locations with EpiPen® (epinephrine) and EpiPen Jr® (epinephrine) Auto-Injectors. Over time, the companies also will introduce a variety of educational resources designed to increase awareness of and preparedness for severe allergic reactions.
EpiPen® locations will roll out at Disney parks and on cruise ships beginning in late 2014. In addition to emergency medical services (EMS), nurses trained to administer EpiPen Auto-Injectors are available during First Aid station operating hours to assist guests experiencing a severe allergic reaction. To help guests identify EpiPen locations, Disney's guide maps will now include an EpiPen Auto-Injector symbol and new signage at First Aid stations.
"Mylan's mission is to provide the world's 7 billion people access to high quality medicine and set new standards in health care. In support of this mission, we are committed to enhancing access to EpiPen Auto-Injectors and to increasing awareness of anaphylaxis. Like life, severe allergic reactions are unpredictable, so people need to be prepared," said Mylan CEO Heather Bresch. "We are very proud to be working with Disney, which already has a strong reputation for meeting the needs of people managing severe allergies, and believe we can further raise awareness of anaphylaxis through this collaboration and our joint commitment to education."
Anaphylaxis is unpredictable, and can progress quickly and without warning. Clinical guidelines state that epinephrine is the first-line treatment when anaphylaxis occurs, making access critical. For those with a known risk, it is important to be prepared with an anaphylaxis action plan that includes 1) avoiding known allergens, 2) recognizing the signs and symptoms of anaphylaxis, 3) having immediate access to two epinephrine auto-injectors, such as EpiPen Auto-Injector, and 4) seeking immediate emergency medical care should anaphylaxis occur.
"For our guests who live with severe allergies every day, identifying EpiPen locations is an additional tool they'll have for their anaphylaxis management plan," said Dr. Pamela Hymel, chief medical officer for Walt Disney Parks and Resorts. "This new strategic alliance will help raise awareness of EpiPen locations so that our Guests with severe allergies may have the best possible experience at our parks and on our cruise ships."
Families managing known severe allergies are encouraged to follow their individual anaphylaxis action plans and carry their epinephrine auto-injectors with them at all times.
EpiPen® (epinephrine) 0.3 mg and EpiPen Jr® (epinephrine) 0.15 mg Auto-Injectors are for the emergency treatment of life-threatening allergic reactions (anaphylaxis) caused by allergens, exercise, or unknown triggers; and for people who are determined to be at increased risk for these reactions. EpiPen and EpiPen Jr are intended for immediate self administration as emergency supportive therapy only. Seek immediate emergency medical treatment after use.
Important Safety Information
EpiPen Auto-Injectors contain a single dose of epinephrine, which you inject into your outer thigh. DO NOT INJECT INTO YOUR VEIN, BUTTOCK, FINGERS, TOES, HANDS OR FEET. In case of accidental injection, please seek immediate medical treatment. Epinephrine should be used with caution if you have heart disease or are taking certain medicines that can cause heart-related (cardiac) symptoms.
Tell your doctor if you have certain medical conditions such as asthma, depression, thyroid disease, Parkinson's disease, diabetes, high blood pressure and heart disease, have any other medical conditions, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Be sure to also tell your doctor all the medicines you take, especially medicines for asthma. If you have certain medical conditions, or take certain medicines, your condition may get worse or you may have longer lasting side effects when you take the EpiPen or EpiPen Jr Auto-Injector.
The most common side effects may include increase in heart rate, stronger or irregular heartbeat, sweating, nausea and vomiting, difficulty breathing, paleness, dizziness, weakness or shakiness, headache, apprehension, nervousness or anxiety. These side effects usually go away quickly, especially if you rest.
Talk to your healthcare professional to see if EpiPen or EpiPen Jr Auto-Injector is right for you.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.
About EpiPen® (epinephrine) Auto-Injector
EpiPen® (epinephrine) and EpiPen Jr® (epinephrine) Auto-Injectors are used for the emergency treatment of life-threatening allergic reactions. Each EpiPen 2-Pak® and EpiPen Jr 2-Pak® contains two single auto-injectors, instructions for use and a training device, with no drug product or needle, to help patients become familiar with the administration technique. EpiPen Auto-Injector should be administered immediately at the first sign of an anaphylactic reaction. EpiPen Auto-Injector is not a substitute for emergency medical treatment. Patients should seek emergency medical attention immediately following administration. EpiPen Auto-Injector has been the No. 1 prescribed epinephrine auto-injector for more than 25 years and has three-step simple instructions for use. For more information about EpiPen Auto-Injector, please visit www.EpiPen.com.
Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. Learn more at mylan.com
About Walt Disney Parks and Resorts
More than 50 years ago, Walt Disney created a new kind of entertainment families could experience together, immersed in detailed atmospheres and vibrant storytelling. His vision now includes a collection of five of the world's leading family vacation destinations – Disneyland Resort, Anaheim, Calif.; Walt Disney World Resort, Lake Buena Vista, Fla.; Tokyo Disney Resort, Urayasu, Chiba, Japan; Disneyland Paris, Marne-la-Vallee, France; and Hong Kong Disneyland Resort, located on Lantau Island. A sixth resort, Shanghai Disney Resort, is currently under construction in Pudong New District, Shanghai. In addition, Walt Disney Parks and Resorts includes the world-class Disney Cruise Line; Disney Vacation Club; Adventures by Disney, a guided group vacation experience to some of the world's most popular destinations; and Walt Disney Imagineering, which creates and designs all Disney parks, resorts, cruise ships, entertainment and attractions.
EpiPen®, EpiPen Jr®, EpiPen 2-Pak® and EpiPen Jr 2-Pak® are registered trademarks of Mylan Inc. licensed exclusively to its wholly-owned subsidiary, Mylan Specialty L.P.